İnsülin benzeri büyüme faktörü miyokard infarktüsünden on ay sonra prognozu etkiler mi?

Year 2020, Volume: 12 Issue: 2, 131 - 137, 01.06.2020

Yücel Yılmaz Mustafa Duran Mustafa Altay Eyüp Özkan Fatih Tanrıverdi Namık Kemal Eryol

https://doi.org/10.21601/ortadogutipdergisi.506160

Abstract

Amaç: Akut miyokard infarktüslü (AMİ) hastalarda insülin benzeri büyüme faktörü-1 (İGF-1) düzeylerini araştırdık ve IGF-1’de bir azalmanın uzun vadeli prognozu etkileyip etkilemeyeceğini belirlemeyi amaçladık.
Yöntemler: AMİ nedeniyle hastanemize başvuran 65 hasta ve 25 sağlıklı kontrol birey çalışmaya dahil edildi. İGF-1 ve insülin benzeri büyüme faktörü bağlayıcı protein-3 (IGFBP-3) seviyelerini belirlemek için AMİ’ den sonra en erken zamanda ve 10 ay sonra tüm hastalardan ve kontrol grubundan kan örnekleri alındı. Hastalar AMİ’ den 10 ay sonra kardiyak olayları açısından değerlendirildi.
Bulgular: İGF-1 düzeyleri, AMI hastalarında sağlıklı kontrollerden daha yüksekti (p = 0,002); 10 ay sonra, hem İGFBP-3 hem de İGF-1 seviyeleri daha yüksekti. Düşük ve yüksek İGF-1 ve IGFBP-3 düzeyleri olan hastalarda kardiyak olay oluşumunda anlamlı fark bulunmadı (hem başlangıç ​​hem de 10 aylık değerler için).
Sonuç: Serum total İGF-1 ve İGFBP-3 düzeyleri, AMİ hastalarında kontrol hastalarına göre daha yüksekti; ancak, İGF-1 ve iGFBP-3 seviyeleri ile AMİ sonrası 10 aylık dönemde kardiyak olaylar arasında korelasyon bulunamadı. AMİ sonrası İGF-1 ve İGFBP-3 düzey normalleşmesi için gereken süreyi netleştirmek ve AMİ sonrası hastaların uzun dönem prognozu üzerindeki etkilerini belirlemek için ilave çalışmalara ihtiyaç vardır.

Keywords

akut miyokard infarktüsü, kardiyak olay, insülin benzeri büyüme faktörü-1

Does insulin-like growth factor influence prognosis ten months after myocardial infarction?

Abstract

Background: We investigated the levels of insulin-like growth factor-1 (IGF-1) in acute myocardial infarction (AMI) patients, and we determined whether a decrease in IGF-1 could influence long-term prognosis.
Methods: In total, 65 patients who were admitted to our hospital for AMI and 25 healthy controls were included in this study. Fasting blood samples were obtained from all patients immediately after AMI and 10 months later to determine their IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels. Fasting blood samples were obtained from the control group. The patients were also evaluated for cardiac events 10 months after AMI.
Results: The IGF-1 levels were higher in the AMI patients than in the healthy controls (p=0.002); after 10 months, both the IGFBP-3 and IGF-1 levels were higher. No differences were found in cardiac event occurrence between patients with low and high IGF-1 and IGFBP-3 levels (for both the baseline and 10-month values).
Conclusions: The serum total IGF-1 and IGFBP-3 levels were higher in the AMI patients compared to the control patients; however, there was no correlation between the IGF-1 and IGFBP-3 levels and cardiac events during the 10-month period after AMI. Additional studies are needed to clarify the time required for IGF-1 and IGFBP-3 level normalization after AMI, and to determine the effects of IGF-1 and IGFBP-3 on the long-term prognosis of patients after AMI.

Keywords

acute myocardial infarction, cardiac events, insulin-like growth factor-1

References

• Conti E, Musumeci MB, De Giusti M, et al. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin. Sci. (Lond). 2011; 120: 377-402.
• Heald AH, Siddals KW, Fraser W, et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes. 2002; 51: 2629-2636.
• Juul A, Scheike T, Davidsen, M, et al. Low serum insulinlike growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106: 939-944.
• Vasan RS, Sullivan LM, D’Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med. 2003; 139: 642-648.
• Bleumink GS, Rietveld I, Janssen JA, et al. Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol. 2004; 94: 384-386.
• Van Bunderen CC, Oosterwerff MM, van Schoor NM, et al. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study. Eur J Endocrinol. 2013; 168: 393-401.
• Friberg L, Werner S, Eggertsen G et al. Growth hormone and insulin-like growth factor-1 in acute myocardial infarction. Eur Heart J. 2000; 21: 1547-1554.
• Lee WL, Chen JW, Ting CT, et al. Wang, Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling. J Clin Endocrinol Metab. 1999: 84: 1575-1581.
• Wang L, Ma W, Markovich R, et al. Chen, P.H. Wang, Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998; 83: 516-522.
• Li B, Setoguchi M, Wang X, et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res. 1999; 84: 1007-1019.
• Colao A. The GH–IGF-I axis and the cardiovascular system: clinical implications. Clinical Endocrinology. 2008; 69: 347-358.
• Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994; 90: 583-612.
• Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res. 1990; 66: 1755-1760.
• Khorsandi MJ, Fagin JA, Giannella-Neto D, et al. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation: evidence for local bioactivity. J Clin Invest. 1992; 90: 1926-1931.
• Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 1991; 88: 9959-9963.
• Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995; 95: 2266-2274.
• Higashi Y, Sukhanov S, Anwar A, et al. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci. 2012; 67: 626-639.
• Kaplan RC, Strickler HD, Rohan TE, et al. Insulin-Like Growth Factors and Coronary Heart Disease. Cardiol Rev. 2005; 13: 35-39.
• Ruidavets JB, Luc G, Machez E, et al. Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study. Atherosclerosis. 2011; 218: 464-469.
• Laughlin GA, Barrett-Connor E, Criqui MH, et al. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004; 89: 114-120.
• Kaplan RC, McGinn AP, Pollak MN, et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007; 92: 1319-1325.
• Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol. 1996; 77: 200-202.
• Goodman-Gruen D, Barrett-Connor E, Rosen C. IGF-1 and ischemic heart disease in older people. J Am Geriatr Soc. 2000; 48: 860-861.
• Janssen JA, Stolk RP, Pols HA, et al. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998; 18: 277-282.
• Botker HE, Skjaerbaek C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vvasospasm, and syndrome X. Am J Cardiol. 1997; 79: 961-963.
• Heald AH, Cruickshank JK, Riste LK, et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001; 44: 333-339.
• Sekuri C, Arslan O, Utuk O, et al. Serum level of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis. Anadolu Kardiyol Derg. 2004; 4: 209-212.
• Yamaguchi H, Komamura K, Choraku M, et al. Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction. Intern Med. 2008; 47: 819-825.
• Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997; 336: 633-640.
• Bornfeldt KE, Raines EW, Nakano T, et al. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994; 93: 1266-1274.
• Muniyappa R, Walsh MF, Rangi JS, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997; 61: 925-931.
• Tsukahara H, Gordienko DV, Tonshoff B, et al. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994; 45: 598-604.
• Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll. Cardiol. 2001; 38: 26-32.